Synonyms:
Status: Phase 1
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: FEH7RQ7B3J

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 1 D064129 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4297728
FDA SRS FEH7RQ7B3J